Procept Biorobotics Corp
NASDAQ:PRCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (23), the stock would be worth $-29.14 (227% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -18.2 | $23.03 |
0%
|
| Industry Average | 23 | $-29.14 |
-227%
|
| Country Average | 23.2 | $-29.37 |
-228%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
P
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
1.3B USD | -18.2 | -13.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 64.1 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 22.2 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 31.3 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 23 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 26.2 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 33.1 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 21.1 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 43.7 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 22.3 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 17.2 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Procept Biorobotics Corp
Glance View
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods. Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
